
BioMarin Pharmaceutical Inc.: updates and filings
Price
$61.42
November 19, 2026Market cap $11.8B
What Ploutos Investor adds for BioMarin Pharmaceutical
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 2, 2026next Feb 3, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
October 2026
September 2026
August 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 4, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 3, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 2, 2026Results of operationsForm8-K
- Oct 6, 2026Results of operationsForm8-K
- Sep 30, 2026Material agreement enteredForm8-K
- Sep 15, 2026Other material eventsForm8-K
- Sep 14, 2026Officer or director changeForm8-K
- Sep 1, 2026Other material eventsForm8-K
- Aug 31, 2026Material agreement entered, Regulation FD disclosureForm8-K
- Aug 18, 2026Material agreement entered, Regulation FD disclosureForm8-K
- Aug 6, 2026Shares registered for employeesFormS-8
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 6, 2026Results of operationsForm8-K
- Jul 13, 2026Other material events (amendment)Form8-K/A
- Jun 4, 2026Officer or director change, shareholder voteForm8-K
- May 5, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 4, 2026Results of operationsForm8-K
- Apr 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 27, 2026Material agreement entered, acquisition or disposal of assets, new material financial obligation, Regulation FD disclosureForm8-K
- Apr 23, 2026Other material eventsForm8-K
- Apr 21, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 21, 2026Additional annual meeting materialFormDEFA14A
- Apr 21, 2026Annual meeting proxy statementFormDEF 14A
- Mar 26, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 16, 2026Other material eventsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 4, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 3, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 2, 2026 | 8-K | Results of operations | Document |
| Oct 6, 2026 | 8-K | Results of operations | Document |
| Sep 30, 2026 | 8-K | Material agreement entered | Document |
| Sep 15, 2026 | 8-K | Other material events | Document |
| Sep 14, 2026 | 8-K | Officer or director change | Document |
| Sep 1, 2026 | 8-K | Other material events | Document |
| Aug 31, 2026 | 8-K | Material agreement entered, Regulation FD disclosure | Document |
| Aug 18, 2026 | 8-K | Material agreement entered, Regulation FD disclosure | Document |
| Aug 6, 2026 | S-8 | Shares registered for employees | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 6, 2026 | 8-K | Results of operations | Document |
| Jul 13, 2026 | 8-K/A | Other material events (amendment) | Document |
| Jun 4, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 5, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 4, 2026 | 8-K | Results of operations | Document |
| Apr 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 27, 2026 | 8-K | Material agreement entered, acquisition or disposal of assets, new material financial obligation, Regulation FD disclosure | Document |
| Apr 23, 2026 | 8-K | Other material events | Document |
| Apr 21, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 21, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 21, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 26, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 16, 2026 | 8-K | Other material events | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC since May 4, 1999: every report, 8-K, meeting and letter. Of its other filings (945 in all), the newest. Of its note and share prospectuses (424B, FWP), the newest 40 of 46.
The full analysis
What do BioMarin Pharmaceutical's filings show?
The filings are where every one of BioMarin Pharmaceutical's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.